Netherlands· NL-13df99f054de
Teizeild 1 mg/ml concentraat voor oplossing voor infusie
A teplizumab product containing teplizumab, registered in Netherlands by Sanofi Winthrop Industrie. The same ATC class is registered in 13 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Teplizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC A10XX01 (teplizumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Teplizumab · ATC A10XX01
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- TEPLIZUMAB
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Netherlands (NL)
- ATC code
- A10XX01
- ATC class
- Teplizumab
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/25/1998
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Teplizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceTEIZEILD 1 mg/1 mL, solution à diluer pour perfusionSANOFI WINTHROP INDUSTRIE
- United StatesTZIELDProvention Bio, Inc.
- CzechiaTEIZEILDSanofi Winthrop Industrie, Gentilly
- SpainTEIZEILD 1 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONSanofi Winthrop Industrie
- FinlandTeizeildSanofi Winthrop Industrie
- BelgiumTeizeild 1 mg/mlSanofi Winthrop Industrie
- IrelandTeizeild 1 mg/mL concentrate for solution for infusionSanofi Winthrop Industrie
- IcelandTeizeildSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Teizeild
- Liechtenstein · Teizeild
- Norway · Teizeild
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9f8b0c5c-780c-4e08-908a-23aaa8557759 GET /v1/drugs/9f8b0c5c-780c-4e08-908a-23aaa8557759?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/teizeild-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Teplizumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134555",
"excipients": [
"DINATRIUMWATERSTOFFOSFAAT 0-WATER (E 339)",
"NATRIUMCHLORIDE",
"NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
"POLYSORBAAT 80 (E 433)",
"WATER VOOR INJECTIE"
],
"substances": [
"TEPLIZUMAB"
],
"leaflet_url": null,
"authorised_at": "2026/01/08",
"procedure_number": "EMEA/H/C/005496",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/25/1998",
"additional_monitoring": "Y"
}See everything about teplizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.